PipelineReview.com3h
Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
BRISBANE, Australia & CAMBRIDGE, MA, USA I8, 2024 I Vaxxas, a clinical-stage biotechnology company commercializing a novel ...
PipelineReview.com3h
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors
SOUTH SAN FRANCISCO, CA, USA I8, 2024 I IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and ...
PipelineReview.com3h
Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates
SAN FRANCISCO, CA, USA I8, 2024 I Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class ...
PipelineReview.com3h
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer’s Disease and Neuroscience Pipeline
NORTH CHICAGO, IL and BOSTON, MA, USA I8, 2024 I AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which ...
PipelineReview.com3h
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications ...
PipelineReview.com8h
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades ...
PipelineReview.com8h
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral ...
PipelineReview.com1d
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
CAMBRIDGE, MA, USA I6, 2024 I Biogen Inc. (Nasdaq: BIIB) – today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an ...
PipelineReview.com3d
Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor
MORRISVILLE, NC, USA I5, 2024 I Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule precision therapeutics to ...
PipelineReview.com3d
Traverse Biotech to Present Data on ROR2-Targeted T-Cell Engager at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
NEW YORK, NY, USA I5, 2024 I Traverse Biotech, Inc., a privately held biotechnology company specializing in innovative immunotherapy solutions, today announced that it will present a poster at the ...
PipelineReview.com3d
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
VANCOUVER, Canada I5, 2024 I Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, ...
PipelineReview.com3d
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
GAITHERSBURG, MD, USA I5, 2024 I LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical ...